Anthracycline Cardiotoxicity: It Is Possible to Teach an Old Dog Some New Tricks

Jose Alvarez-Cardona, Daniel J. Lenihan

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Anthracyclines have proved to be one of the most effective chemotherapeutic agents in the treatment of numerous solid tumors and hematologic malignancies in both adult and pediatric patients. Their clinical benefit, however, is sometimes hampered by the development of cardiotoxicity, a process that still remains elusive despite decades of investigation. It has been postulated that anthracycline-induced cardiotoxicity is mediated in part by reactive oxygen species and redox cycling. This article reviews anthracycline cardiotoxicity in terms of historical significance, epidemiology, current detection strategies, prevention strategies, and patient care after anthracycline-based chemotherapy.

Original languageEnglish
Pages (from-to)355-363
Number of pages9
JournalCardiology clinics
Issue number4
StatePublished - Nov 2019


  • Anthracycline cardiotoxicity
  • Cardioprotection
  • Chemotherapeutic agents
  • Left ventricular ejection fraction (LVEF)


Dive into the research topics of 'Anthracycline Cardiotoxicity: It Is Possible to Teach an Old Dog Some New Tricks'. Together they form a unique fingerprint.

Cite this